Telix Pharmaceuticals
Telix Pharmaceuticalsis a clinical-stage biotechnology company focused on the development of diagnostic and therapeutic products.
Raised 425.08M CONVERTIBLE_NOTE on July 26, 2024
About
Telix Pharmaceuticals is an Australian biopharmaceutical company developing and commercializing radiopharmaceuticals and radionuclide-targeted molecular drug‑conjugates for radiolabeled cancer diagnosis and therapeutic applications.
Mission
Telix Pharmaceuticals is an Australian biopharmaceutical services firm focused on radiopharmaceuticals and novel radionuclide‑targeted molecular drug‑conjugate technology. The company uses this platform to develop and apply radiolabeled conjugates in cancer diagnosis and therapy. Telix announced the successful issuance of convertible bonds valued at A$650 million (approximately RMB 3.1 billion). The financing represents a material capital raise reported by the company in the article. The article does not disclose operating metrics, revenue, or details on planned use of proceeds.
Quick Facts
Founded
2015
Funding
CONVERTIBLE_NOTE
Industry
Biotechnology
Team Size
101-250
Headquarters
Melbourne, Victoria, Australia
Careers
View Careers Page
Telix Pharmaceuticals
https://jobs.ashbyhq.com/telixpharmaNo open roles at this time.
Check their careers page for updates